|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismFGFR2 stimulants |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
冻干重组人角质细胞生长因子血液肿瘤患者耐受性、药代动力学I/II期临床试验
[Translation] Phase I/II clinical trial on the tolerability and pharmacokinetics of freeze-dried recombinant human keratinocyte growth factor in patients with hematological malignancies
主要目的是针对接受自体造血干细胞移植治疗的血液肿瘤患者,考察对冻干重组人角质细胞生长因子的耐受性,探索最大耐受剂量,其次为初步探索疗效和评价药代动力学特征。
[Translation] The main purpose is to investigate the tolerance of lyophilized recombinant human keratinocyte growth factor and explore the maximum tolerated dose in patients with blood malignancies who are receiving autologous hematopoietic stem cell transplantation, followed by preliminary exploration of efficacy and evaluation of pharmacokinetic characteristics.
冻干重组人角质细胞生长因子在健康受试者I期临床耐受性、药代动力学及初步药效学试验
[Translation] Phase I clinical tolerability, pharmacokinetics and preliminary pharmacodynamics study of lyophilized recombinant human keratinocyte growth factor in healthy subjects
考察健康受试者接受单次和多次注射不同剂量冻干重组人角质细胞生长因子的耐受性、药代动力学及初步药效学。
[Translation] To investigate the tolerability, pharmacokinetics and preliminary pharmacodynamics of single and multiple injections of different doses of freeze-dried recombinant human keratinocyte growth factor in healthy subjects.
100 Clinical Results associated with Chengdu Zhitian Bioengineering Co., Ltd.
0 Patents (Medical) associated with Chengdu Zhitian Bioengineering Co., Ltd.
100 Deals associated with Chengdu Zhitian Bioengineering Co., Ltd.
100 Translational Medicine associated with Chengdu Zhitian Bioengineering Co., Ltd.